Clinical Trial Detail

NCT ID NCT02921022
Title Study Of Gemcitabine, Nab-paclitaxel, PEGPH20 and Rivaroxaban for Advanced Pancreatic Adenocarcinoma
Recruitment Active, not recruiting
Gender both
Phase Phase 0
Variant Requirements No
Sponsors Memorial Sloan Kettering Cancer Center
Indications

pancreatic ductal adenocarcinoma

Therapies

Gemcitabine + Nab-paclitaxel + PEGPH20

Age Groups: adult senior

No variant requirements are available.